Polymers as drugs

被引:35
作者
Dhal, PK [1 ]
Holmes-Farley, SR [1 ]
Huval, CC [1 ]
Jozefiak, TH [1 ]
机构
[1] Genzyme Corp, Drug Discovery & Dev, Waltham, MA 02451 USA
来源
POLYMER THERAPEUTICS I: POLYMERS AS DRUGS, CONJUGATES AND GENE DELIVERY SYSTEMS | 2006年 / 192卷
关键词
bioactive polymers; drugs; non-absorbed; polyvalent; sequestrants;
D O I
10.1007/12_020
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Polymeric drugs are defined as polymers that are active pharmaceutical ingredients, i.e., they are neither drug carriers nor prodrugs. In general, the underlying concept behind these therapeutic agents is the utilization of high molecular weight and functional characteristics of polymers to selectively recognize, sequester, and remove low molecular weight and macromolecular disease causing species in the intestinal fluid. The high molecular weight nature of these therapeutically relevant polymers makes them systemically non-absorbed, thus providing a number of advantages including long-term safety profiles over traditional small molecule drug products. Furthermore, multiple functional groups in the polymers incorporate polyvalent binding interactions that can result in pharmaceutical properties not found in small molecule drugs. This article summarizes some of the most recent efforts for the discovery and development of polymeric drugs that have proceeded from discovery phase to market place. Examples include sequestration of low molecular weight species such as bile acids, phosphate, and iron ions as well as polyvalent interactions to bind toxins, viruses, and bacteria as well as polymeric enzyme inhibitors and fat binders as anti-obesity agents. Furthermore, use of functional polymers to treat autoimmune disease and sickle cell anemia has been reviewed.
引用
收藏
页码:9 / 58
页数:50
相关论文
共 174 条
[1]   Update on Clostridium difficile infection. [J].
Alcantara C.S. ;
Guerrant R.L. .
Current Gastroenterology Reports, 2000, 2 (4) :310-314
[2]   The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure [J].
Amin, N .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (02) :340-345
[3]   Multi-valent polymer of vancomycin: enhanced antibacterial activity against VRE [J].
Arimoto, H ;
Nishimura, K ;
Kinumi, T ;
Hayakawa, I ;
Uemura, D .
CHEMICAL COMMUNICATIONS, 1999, (15) :1361-1362
[4]   Affinity of a vancomycin polymer with bacterial surface models [J].
Arimoto, H ;
Oishi, T ;
Nishijima, M ;
Kinumi, T .
TETRAHEDRON LETTERS, 2001, 42 (19) :3347-3350
[5]  
BACONKURTZ C, 2001, Patent No. 6290946
[6]  
BADMAN DG, 2000, IRON CHELATORS NEW D
[7]   Orlistat: its current status as an anti-obesity drug [J].
Ballinger, A ;
Peikin, SR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 440 (2-3) :109-117
[8]   CLOSTRIDIUM-DIFFICILE - HISTORY OF ITS ROLE AS AN ENTERIC PATHOGEN AND THE CURRENT STATE OF KNOWLEDGE ABOUT THE ORGANISM [J].
BARTLETT, JG .
CLINICAL INFECTIOUS DISEASES, 1994, 18 :S265-S272
[9]   Colesevelam HCl: a non-systemic lipid-altering drug [J].
Bays, H ;
Dujovne, C .
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (05) :779-790
[10]  
Beer PD, 2001, ANGEW CHEM INT EDIT, V40, P486, DOI 10.1002/1521-3773(20010202)40:3<486::AID-ANIE486>3.3.CO